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Until recently, most immunotherapeutic approaches used to fight cancer were ineffective, counteracted by the
tumour’s ability to evade immune attack. However, extensive research has improved our understanding of tumour
immunology and enabled the development of novel treatments that can harness the patient’s immune system and
prevent immune escape. Over the last few years, through numerous clinical trials and real-world experience, we
have accumulated a large amount of evidence regarding the potential for long-term survival with immunotherapy
agents in various types of malignancy. The results of these studies have also highlighted a number of recurring
observations with immuno-oncology agents, including their potential for clinical application across a broad patient
population and for both conventional and unconventional response patterns. Furthermore, given the numerous
immune checkpoints that exist and the multiple mechanisms used by tumours to escape the immune system,
targeting distinct checkpoint pathways using combination approaches is an attractive therapeutic strategy with the
potential to further enhance the antitumour immune response.
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Exploiting the immune system’s ability to identify and des-
troy tumours using immunotherapy has long been recog-
nised as a promising approach to anticancer treatment [1].
However, traditional immunotherapies such as interferon
and interleukin-2 have generally failed to demonstrate
consistent clinical benefit in advanced stage cancer.
The recent renaissance of cancer immunotherapy can be
largely attributed to the development of novel immuno-
therapy agents which target specific immune regulatory
checkpoints to enhance the endogenous antitumour im-
mune response. After becoming the first agent to demon-
strate a significant overall survival (OS) improvement in a
randomised phase 3 trial in metastatic melanoma [2], the
anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody
ipilimumab was approved for this indication (although,
in Europe, its initial indication was restricted to patients
who had received prior therapy) [3]. In the last 3 years,* Correspondence: paolo.ascierto@gmail.com
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article, unless otherwise stated.we have gained a wealth of experience with this and other
immunotherapies in the clinical setting and learned a con-
siderable amount regarding their potential benefit across
multiple tumour types.
CTLA-4 is a key inhibitory checkpoint molecule that
is thought to counteract the co-stimulatory signal from its
homologue, CD28, by competitively binding to its ligands
(B7.1 and B7.2) on the surface of antigen-presenting cells
[4]. Tumour cells exploit this pathway to turn off the im-
mune response by suppressing the activation and prolifer-
ation of conventional T cells and promoting the function
of regulatory T cells (Tregs) which can dampen the
immune response at the tumour site [5,6]. By blocking
CTLA-4, ipilimumab restores the co-stimulatory activ-
ity of CD28, thereby increasing the number of activated
T cells that can migrate to and attack the tumour [7].
Recent data have also demonstrated that treatment with
CTLA-4 antibodies can mediate selective depletion of
Treg cells within the tumour [8].
In addition to CTLA-4, numerous other immune check-
points exist that are potential targets for immunotherapy
[9,10]. For example, interaction of the programmed death
1 (PD1) receptor with its ligands (PDL1 and PDL2) in per-
ipheral sites leads to T-cell inactivation and loss of effectored Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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PD1 (e.g. nivolumab, pembrolizumab) or PDL1/PDL2 (e.g.
MPDL3280A, MEDI4736) breaks down this mechanism,
preventing T-cell inactivation and restoring immune
activity directly at the tumour site [11]. Immunotherapies
targeting other immune checkpoint molecules such as
LAG3 and CD137 (4-1-BB) are also under evaluation
in advanced malignancies, either as monotherapy or in
combination with other therapies (Figure 1).
Adoptive T cell therapy (ATC) using chimeric antigen
receptors (CARs) is an alternative immunotherapeutic
approach to anticancer therapy. This approach combines
the antigen-binding property of monoclonal antibodies
with the lytic capacity and self-renewal of T cells [13].
Clinical trials have revealed promising results in patients
with CD19-positive haematological malignancies, includ-
ing non-Hodgkin’s lymphoma, chronic lymphocytic leu-
kaemia, and acute lymphoblastic leukaemia; further trials
in patients with B-cell malignancies or solid tumours are
ongoing [13].
ATC therapy using autologous ex vivo-expanded tumour
infiltrating lymphocytes (TILs) that are then adoptively
transferred back into patients is an immunotherapy that
has shown clinical efficacy in metastatic melanoma [14].
In one study, the immunodominant epitope recognised by
the tumour-reactive T-cells was identified as a mutated
protein phosphatase 1, regulatory (inhibitor) subunit 3B
(PPP1R3B) gene product; the patient achieved a durable
complete response with regression of bulky liver tumour
mass [15].
Efforts to determine an effective vaccine that alerts the
immune system to cancer cells have largely failed; however,Figure 1 Immuno-oncology agentsa in clinical development across mult
additional agents are, for example in phase 1 studies in patients with solid tum
leukaemia; CRC, colorectal cancer; CRPC, castration-resistant prostate cancer; CT
tumour; HCC, hepatic cell carcinoma; LAG-3, lymphocyte activation gene 3; mA
cell lung cancer; PC, prostate cancer; PD1, programmed death 1; RCC, renal celexperimental cancer vaccines containing proteins that are
overexpressed by tumour cells may work synergistically
with other immunotherapies [16,17]. Talimogene laher-
parepvec (T-VEC) is a genetically modified virus which
drives the secretion of the immunostimulatory cytokine
granulocyte macrophage colony stimulating factor (GM-
CSF) [18]. T-VEC is currently being evaluated as a poten-
tial treatment in melanoma and other advanced cancers
[19,20]. In a pre-clinical study in breast cancer bearing
mice, the combination of an anti-PD1 antibody and a
multi-peptide vaccine prolonged the vaccine-induced
progression-free survival (PFS) by altering both the CD8
T-cell and dendritic cell components of the tumour
microenvironment [21].
Currently, the American Joint Committee on Cancer
(AJCC)/International Union Against Cancer (UICC)
tumor-node-metastasis (TNM) classification provides lim-
ited prognostic information and does not predict response
to therapy. However, it is now becoming clear that the
host-immune reaction to tumours is a critical element
in determining response to therapy. This has led to the
development of an ‘Immunoscore’ which correlates
immune-cell infiltration in tumors to patient’s clinical
outcome. Recent work has reported that such an immune-
classification has a prognostic value that may be superior
to the AJCC/UICC TNM-classification, and studies are
ongoing to validate and integrate such a system into
clinical practice [22].
Responses to immunotherapy may be delayed or may
develop after a period of apparent disease progression
due to the time required to build an effective immune re-
sponse; therefore, tumour assessments should be performediple tumour types. aSelected therapies and tumour types are shown:
ours [12]. AML, acute myeloid leukemia; CLL, chronic lymphocytic
LA-4, cytotoxic T-lymphocyte antigen-4; GIST, gastrointestinal stromal
b, monoclonal antibody; NHL, non-Hodgkin lymphoma; NSCLC, non-small
l carcinoma; SCLC, small cell lung cancer.
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sults confirmed with a follow-up scan [23]. For ipilimumab,
the recommended induction regimen is 3 mg/kg, adminis-
tered every 3 weeks for 4 doses; this is sufficient to provide
a considerable survival benefit in a proportion of patients
[2,3]. To maximise clinical benefit, it is also recommended
that ipilimumab is administered for the entire induction
regimen as tolerated, regardless of the appearance of new
lesions or growth of existing lesions, as immune cell infiltra-
tion following immunotherapy may be mistaken for tumour
progression [24]. In addition, the unconventional nature of
some responses with ipilimumab have made it necessary to
introduce new criteria to characterise antitumour activity,
as conventional assessment methods may not fully capture
these novel response patterns. Immune-related response
criteria (irRC) were developed from existing modified
World Health Organisation (mWHO) criteria; the irRC
allow for initial tumour progression or appearence of new
lesions, both of which would be considered as progressive
disease according to mWHO criteria [23]. Although irRC
were developed based on response patterns observed with
ipilimumab, the possibility of unconventional, immune-
related response patterns must be also considered for other
immunotherapies, including nivolumab and other anti-
PD1/PDL1 agents. Indeed, responses with nivolumab mayFigure 2 Kaplan-Meier curves of OS in patients treated with ipilimum
patients with metastatic melanoma: A) MDX010-20 trial, and B) CA184-024be rapid or delayed, and may continue after therapy is
discontinued [25].
An emerging understanding of the biology affecting
the results of immunotherapy leads to the conclusion
that surrogate endpoints such as objective response rates
and PFS may not be appropriate for measuring long-
term treatment benefit [26]. Data from clinical trials and
ipilimumab expanded access programmes (EAPs) indi-
cate that long-lasting stable disease is a common out-
come with immunotherapy and that, even in the absence
of a complete or partial tumour response, durable dis-
ease control can result in prolonged OS [23,27]. Efficacy
endpoints that better correlate with prolonged survival,
such as landmark survival analyses are therefore becom-
ing more relevant since they take into consideration the
durability of survival [26].
Kaplan-Meier curves of OS in patients treated with
ipilimumab show that survival consistently reaches a
plateau at around 2–3 years [2,28-31], as demonstrated in
both randomised phase 3 trials of ipilimumab in meta-
static melanoma (Figure 2). Beyond this time point, the
long ‘tail’ of the survival curve reflects the emergence of
long-term survivors and highlights the importance of
using landmark survival analyses as well as hazard ratios
and median OS, to benchmark survival outcomes. In aab. OS curves from two randomised phase 3 trials of ipilimumab in
trial.
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tients with metastatic castration-resistant prostate cancer
(mCRPC), the 2-year survival rate with ipilimumab was
26%, compared with 15% for patients in the placebo arm
[32]. Furthermore, in a recent meta-analysis of 1,861 pa-
tients with metastatic melanoma who received ipilimumab
in phase 2 and phase 3 trials, the 3-year survival rate was
22% and around one fifth of patients survived for up to
10 years, irrespective of prior treatment [33]. Notably,
inclusion of EAP data did not affect the overall shape of
the pooled survival curve, indicating that the potential for
long-term survival persists even in patients with a particu-
larly poor prognosis. In both the meta-analysis and the
prostate cancer trial, the shape of the OS curves for
ipilimumab-treated patients appeared remarkably similar
to those seen in the pivotal phase 3 trials in melanoma.
Additional data from clinical trials suggest that targeting
other immune checkpoints can provide long-term survival
benefits. For example, in a phase 1 clinical trial evaluating
nivolumab in patients with advanced solid tumours,
the 2-year survival rates were 14% in non-small cell
lung cancer (NSCLC), 43% in melanoma, and 50% in
renal cell carcinoma (RCC) [34,35]. At present, no me-
dian OS or long-term survival data are available for
pembrolizumab; however, rapid and durable tumour
regressions have been observed with this agent as well
as with nivolumab. Indeed, durable objective responses
may be considered a key endpoint in the future as we
enter a new era of immunotherapy requiring more strin-
gent evaluation [36]. With regard to other immunother-
apies, in an interim survival analysis from a phase 3 trial
of T-VEC versus GM-CSF in patients with advanced
melanoma, the 3-year survival rates were 41% and 28%
for patients treated with T-VEC and GM-CSF, respect-
ively [19,20]. These results are extremely encouraging for
patients with advanced malignancies and have fuelled
speculation that the availability of novel immunotherapies
could potentially result in cancer turning into a con-
trollable chronic disease in a considerable proportion
of patients.
Evidence suggests that a number of immuno-oncology
approaches do not require identification of specific tumour
antigens and thus provide the potential to offer clinical
benefit across many different types of cancer. Based on this
rationale, monoclonal antibodies targeting a variety of im-
mune checkpoints inhibitors (e.g. anti-CTLA-4, anti-PD1,
and anti-LAG3) have been investigated across multiple
tumour types, including prostate cancer, lung cancer and
RCC [32,34,37-42]. For example, in a phase 3 trial in pa-
tients with mCRPC, ipilimumab treatment improved PFS
and prostate specific antigen (PSA) responses versus pla-
cebo when administered after a single dose of radiotherapy
(RT). Although the primary endpoint of improved OS
was not met (the hazard ratio for OS versus placebo was0.85; P = 0.05), the results of an OS subgroup analysis
suggested that patients with a lower disease burden may
be more likely to benefit from ipilimumab treatment
[32]; an ongoing phase 3 trial of ipilimumab in patients
with chemotherapy-naïve mCRPC is prospectively evalu-
ating this patient population.
Encouraging results have also been observed in ipilimu-
mab clinical trials in patients with advanced lung cancer.
In a phase 2 trial, there was a trend towards improved sur-
vival in patients who received ipilimumab 10 mg/kg after
carboplatin and paclitaxel (CP) compared with CP alone
[38,39]; two randomised phase 3 trials to evaluate ipilimu-
mab in NSCLC (NCT01285609) or SCLC (NCT01450761)
are open for enrollment.
Among other investigational immunotherapies, the anti-
PD1 antibody nivolumab has been evaluated in a variety
of tumour types. In the phase 1 trial described earlier,
median OS was 9.6 months, 16.8 months and >22 months,
in patients with NSCLC, melanoma and RCC, respectively
[34,35]; phase 3 trials of nivolumab in each of these indi-
cations are currently ongoing. Other immune checkpoint
inhibitors, including other anti-PD1/PDL1 agents, anti-
LAG3 antibodies and anti-KIR antibodies, are also under
evaluation in various solid tumours and haematological
malignancies.
As immunotherapy works to enhance the host’s own
immune system rather that acting directly on the tumour
itself, immuno-oncology approaches have the potential
to be effective across patient subpopulations, regardless
of mutational status (e.g. BRAF/NRAS) or histological
subtype. In melanoma, BRAF inhibitors (vemurafenib and
dabrafenib) can provide rapid responses in the 40–50% of
patients with a mutation in BRAF V600; however, their
use is contra-indicated in patients with wild-type BRAF
status [43-45]. By contrast, BRAF or NRAS mutation
status does not appear to be associated with the clinical
activity of ipilimumab (Table 1). In a retrospective mul-
ticentre analysis, there was no difference in median OS
between patients with BRAF/NRAS-mutated or wild-type
melanoma (10.12 months versus 10.18 months) treated
with anti-CTLA-4 antibodies [46]. Similarly, disease con-
trol rates and survival were comparable between BRAF/
NRAS mutant and wild-type patients in the Italian EAP;
safety results were consistent across all groups with
respect to mutational status [47].
BRAF mutations are uncommon in patients with non-
cutaneous (uveal or mucosal) melanomas [64]; therefore,
BRAF inhibitors may have limited utility in these patient
populations. Although clinical trial data regarding the
use of novel therapies in patients with noncutaneous
melanoma are limited, data from EAPs suggest ipilimu-
mab has a similar efficacy and safety profile in patients
with advanced uveal or mucosal melanoma to that ob-
served in cutaneous melanoma [50,51,53-55,57]. In EAP
Table 1 Clinical trial and real-world data on the use of ipilimumab in patient subpopulations
Patient subgroup Efficacy summary Safety summary References
Elderly patients Italian EAP (>70 years)
DCR: 38% Generally well tolerated; consistent
with wider EAP
Chiarion Sileni et al., 2014 [48]
1- year OS: 38%
2-year OS: 22% population
Spanish EAP (≥65 years)
DCR: 35% No increase in toxicity in elderly patients Lopez Martin et al., 2012 [49]
1- year OS: 21%
US EAP (≥65 years) Consistent with wider EAP population Lawrence et al., 2012 [50,51]
1- year OS: 37%
NYU retrospective analysis Chandra et al., 2013 [52]
(≥65 years) Consistent with published data
in younger cohorts
DCR: 36%
Uveal melanoma Italian EAP
DCR: 34% Safety profile similar to that in
cutaneous melanoma
Maio et al., 2013 [53]
1- year OS: 31%
I-OMEAP (10 mg/kg) Consistent with ipilimumab clinical trials Danielli et al., 2012 [54]
DCR: 23%
Royal Marsden Consistent with ipilimumab clinical trials Khattak et al., 2013 [55]
DCR: 20%
US EAP 1- year OS: 34% Consistent with wider EAP population Lawrence et al., 2012 [50,51]
Multicentre retrospective analysis Luke et al., 2013 [56]
DCR: 46% Consistent with ipilimumab clinical trials
Mucosal melanoma Italian EAP
DCR: 36% Safety profile similar to that in
cutaneous melanoma
Del Vecchio et al., 2013 [57]
1- year OS: 35%
US EAP 1- year OS: 32% Consistent with wider EAP population Lawrence et al., 2012 [50,51]
Multicentre experience Postow et al., 2013 [58]
DCR: 27% Consistent with ipilimumab clinical trials
Brain metastases CA184-042 phase 2 trial (asymptomatic)
DCR: 25% Safety results consistent with those
previously reported in clinical trials
Margolin et al., 2012 [59]
1- year OS: 36%
2-year OS: 21%
NIBIT-M1 phase 2 trial
(+fotemustine; asymptomatic)
DCR: 50%
1- year OS: 55% AEs generally manageable and reversible Di Giacomo et al., 2012 [60]
2-year OS: 39% Di Giacomo et al., 2013 [61]
Italian EAP DCR: 27% Safety results consistent with those
previously reported in clinical trials
Queirolo et al., 2014 [62]
1- year OS: 20%
US EAP 1- year OS: 25% Consistent with wider EAP population Lawrence et al., 2012 [50,51]
BRAF/NRAS-mutated
melanoma
Phase 2 study CA184-004
(BRAF mutated vs BRAF wild-type) Shahabi et al., 2012 [63]
DCR: 30% vs 35%
NIBIT-M1 phase 2 trial
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Table 1 Clinical trial and real-world data on the use of ipilimumab in patient subpopulations (Continued)
(+fotemustine; asymptomatic) Di Giacomo et al., 2013 [61]
(BRAF mutated vs BRAF wild-type)
DCR: 60% vs 46%
Italian EAP
(BRAF mutated vs BRAF wild-type) Consistent regardless of
BRAF and NRAS mutation status
Queirolo et al., 2014 [62]
DCR: 38% vs 39%
1-year OS: 48% vs 39%
(NRAS mutated vs NRAS wild-type)
DCR: 57% vs 49%
1-year OS: 43% vs 40%
4 institution retrospective analysis
(ipiliumab or tremelimumab)
Similar median OS between patients with
BRAF/NRAS-mutated and BRAF/NRAS
wild-type melanoma; trend towards improved
OS in wild-type population without prior
BRAFi/MEKi treatment
Mangana et al., 2013 [46]
AEs, adverse events; BRAFi, BRAF inhibitor; DCR, disease control rate; EAP, expanded access programme; I-OMEAP, ipilimumab-ocular melanoma expanded access
program; MEKi, MEK inhibitor; NYU, New York University; OS, overall survival.
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mucosal melanoma were 31% and 35%, respectively; these
values are similar to those reported in the US EAP (34%
and 32%, respectively) [50,53,57].
Subgroup analyses from the registrational phase 3 trial
(MDX010-20) also suggest ipilimumab provides a consist-
ent survival benefit across patient populations, including
those with a historically poor prognosis (e.g. elevated lac-
tate dehydrogenase or poor performance status) [2,65]. In
addition, ipilimumab has demonstrated activity in elderly
patients and patients with stable asymptomatic brain
metastases, providing further support for the potential
benefit with immunotherapy in a broad patient popula-
tion [50,52,58,60,62]. With respect to the clinical activ-
ity of other immuno-oncology agents, in a phase 1 trial
in patients with advanced solid tumours, objective re-
sponse rates with nivolumab in NSCLC were similar
across different patient groups and histology types [66].
Based on their mechanisms of action and available
clinical data, immunotherapy agents may provide greatest
clinical benefit if used as early as possible in the treatment
paradigm when patients have a better prognosis. Further-
more, patients who eventually undergo disease progression
after immunotherapy may have prolonged survival, which
may allow the opportunity to receive and potentially bene-
fit from subsequent lines of therapy. In MDX010-20, ipili-
mumab, with or without gp100, significantly improved
median OS compared with gp100 alone despite similar
estimates of median progression-free survival among the
three treatment arms [2]. This may suggest that, even in
some patients without an objective response or stabledisease, immunotherapy can prolong survival by slowing
the rate of disease progression.
Unlike targeted agents, immuno-oncology agents do
not alter the nature of tumour cells, which could other-
wise select for rapid disease kinetics. Therefore, initial
treatment with immunotherapy does not compromise
the ability of patients to respond to subsequent therapy
with a BRAF inhibitor. Conversely, around 40% of patients
with advanced melanoma who progress after BRAF inhibi-
tor treatment undergo rapid disease progression and thus
are unable to complete ipilimumab therapy. In a retro-
spective analysis of 34 patients with BRAF-mutated mel-
anoma, among 28 patients who received a BRAF inhibitor
followed by ipilimumab, 12 patients (43%) had rapid
disease progression and were not able to complete ipili-
mumab treatment. Median OS for patients with rapid
progression was 5.7 months, compared with 18.6 months
for patients who were able to complete ipilimumab
treatment. By comparison, none of the six patients who
received ipilimumab followed by a BRAF inhibitor had
rapid disease progression and all had disease control
after subsequent treatment with a BRAF inhibitor [67].
Similar results were observed in the Italian EAP, whereby
median OS was 9.9 and 14.5 months, respectively, for
patients who received a BRAF inhibitor before or after
ipilimumab treatment. Among 45 patients who received
a BRAF inhibitor first, median OS from the end of BRAF
inhibitor treatment was significantly longer in patients who
were able to complete ipilimumab treatment compared
with those who had rapid progression and were unable
to complete ipilimumab therapy (12.7 versus 1.2 months;
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using immunotherapy first followed by targeted therapy in
patients with more indolent disease may therefore offer
the best chance of long-term survival [67-71].
Prior exposure to ipilimumab does not appear to
affect outcomes to subsequent anti-PD1 antibody ther-
apy. For example, in a phase 1 expansion study in 135
patients with advanced melanoma who received pem-
brolizumab, efficacy and safety in 48 patients who had
received prior treatment with ipilimumab was similar to
that observed in the 87 patients who were ipilimumab
treatment-naïve [36].
Although typically used only as palliative therapy or in
patients with CNS metastases, there is some evidence to
suggest that administering RT after iplimumab may provide
additional clinical benefit. For example, in a retrospective
analysis of 21 patients who received locoregional RT after
progressing on ipilimumab, 11 patients (52%) showed evi-
dence of a systemic objective response or prolonged stable
disease outside of the irradiated area [72]. This so-called
‘abscopal effect’ has also been observed in isolated patient
cases when RT has been administered either before or after
ipilimumab therapy, suggesting that RT and ipilimumab
have potentially synergistic effects on antitumour immunity
[73,74].
Ongoing research in oncology focuses on enhancing
the proportion of patients who benefit from treatment
with immunotherapy. As already eluded to, combining
immunotherapies with other treatment modalities such
as radiotherapy, chemotherapy or targeted agents could
potentially lead to enhanced efficacy as these treatments
may have immune-stimulatory properties. Increasing pre-
clinical and clinical evidence suggests that these treat-
ments may have additive effects when administered in
combination with immunotherapy [60,73-76].
Given the numerous immune checkpoints that exist,
combining immuno-oncology agents that target different
checkpoint pathways is also an attractive therapeutic ap-
proach. Tumours exploit these pathways to turn off the
immune response in different ways, either by decreasing
T-cell proliferation or inactivating T cells at the tumour
site [77]. For example, by inhibiting CTLA-4, ipilimumab
promotes T-cell proliferation, increasing the number of
activated T cells that can migrate to attack the tumour;
conversely, anti-PD1 agents such as nivolumab counter-
act tumour defences specifically within the tumour micro-
environment, reactivating T-cell activity and inducing
tumour cell death [9,11]. The complementary roles of
these two pathways in regulating adaptive immunity are
supported by preclinical models in which simultaneous
administration of anti-CTLA-4 and anti-PD1 antibodies
resulted in enhanced antitumour activity compared with
single agent treatments [78,79]. In a phase 1 combination
study of ipilimumab and nivolumab in patients withadvanced melanoma, 40% of patients treated with the
concurrent combination regimen had objective responses
and the 1-year OS rate was 82%; notably, responses with
the combination were both rapid and deep [80,81]. This
combination is being further evaluated versus ipilimumab
or nivolumab monotherapy in a phase 3, randomised trial.
Accumulating preclinical and clinical data also support
the use of other investigational immunotherapy combina-
tions such as nivolumab plus anti-LAG3 and ipilimumab
plus GM-CSF [82,83].
Finally, biomarker discovery efforts may help to iden-
tify patients who are most likely to benefit from treatment
with immunotherapy; immunological markers measured
during treatment could also be useful as surrogate markers
of clinical response. However, identification of immuno-
therapy biomarkers is challenging due to the complexity of
interactions between the immune system and tumour cells,
as well as difficulties in performing standardised immuno-
logical assays [84]. At present, no predictive biomarkers
have been validated that can be used to guide patient selec-
tion for treatment with immunotherapy. Although there
are some data to suggest that objective response rates with
nivolumab, either as monotherapy or in combination with
ipilimumab, are highest in patients with positive PDL1
expression in NSCLC and melanoma, the absence of
this marker is not an indication that patients will fail to
respond to treatment [85,86].
Given that immunotherapy appears to be effective in a
broad patient population, the use of biomarkers to guide
treatment selection may not be as relevant for immuno-
therapies as it is for targeted agents such as BRAF or
MEK inhibitors. However, despite the lack of any defini-
tive predictive biomarkers, several immunological parame-
ters have been identified that may serve as early markers
of response. For example, increases in absolute lympho-
cyte count and in the number of circulating T cells that
express inducible T-cell costimulator during ipilimumab
induction therapy have been found to be associated with
higher response rates and/or improved survival outcomes
[27,87-89]. Further prospective, controlled studies are
needed to determine whether changes in these markers
can be used to predict treatment effects.
Conclusion
Over recent years, immunotherapy has increasingly been
acknowledged as the fourth pillar of treatment in advanced
cancer alongside surgery, radiotherapy, and chemotherapy,
with ipilimumab in advanced melanoma serving as the
model for proof of concept. Since the approval of ipili-
mumab in 2011, a number of post-approval issues of
importance to practitioners have arisen, many of which
are related to the mechanism of action of immuno-
oncology agents. Among these is the potential for im-
munotherapy to show clinical activity in all subpopulations
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munotherapy approaches may also allow the opportunity
to slow disease progression and prolong survival even in
patients with progressive disease. Another related issue
which concerns clinicians is how to optimise the sequen-
cing of treatment with ipilimumab and BRAF inhibitors,
with increasing evidence to suggest that clinical benefit
may be optimised by administering immunotherapy agents
as early as possible in the treatment paradigm. In conclu-
sion, immunotherapy agents may represent the future stan-
dards of care for various solid tumours or haematological
malignancies, with the potential for providing a meaningful
survival benefit. Various strategies combining immune
checkpoint regulators with other complementary immuno-
therapies or different treatment modalities are under
investigation to maximise treatment outcomes.
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